Abstract

Drug-eluting stents (DES) have been widely applied for saving the life of patients with coronary artery diseases (CADs). However, conventional polymers such as polylactic acid (PLA) and poly (lactic-co-glycolic acid) (PLGA), which are widely applied for drug-eluting stents studies, have serious bulk erosion problems, like high local acidity and poor mechanical properties. Instead, we chose surface erosion polymer poly (1, 3-trimethylene carbonate) (PTMC) as a drug carrier in this study. Here, we fabricated and characterized a novel durable-polymer drug-eluting 316 L stainless steel (SS) stent, in which the inner surface was coated with a Ti–O film using the magnetron sputtering method to promote the growth of endothelial cells (ECs). On the outer layer of the stent, first, a Ti–O film was deposited and, then, on top of it a rapamycin-loaded PTMC coat was deposited using the ultrasonic atomization spray method. This dual coating inhibited the migration and expansion of smooth muscle cells (SMCs). The drug coating also inhibited the adhesion/activation of platelets. In tests on dogs, it was found the novel stent promoted re-endothelialization and reduced restenosis, in contrast to the plain SS stent. Thus, the novel stent may have promise for use in treating patients with CAD.

Highlights

  • Coronary artery diseases (CADs) are one of the major causes of human death and disability in the world [1,2]

  • PTMC/rapamycin drug coatings were sprayed on one side of the stents facing the vascular surface to inhibit smooth muscle cells from the outer layer, and Ti–O

  • The related evaluation of platelet adhesion, GMP140, Lactate dehydrogenase (LDH), and γ-chain assays indicated that PTMC/rapamycin drug coating can hinder platelet adhesion, activation, and aggregation

Read more

Summary

Introduction

Coronary artery diseases (CADs) are one of the major causes of human death and disability in the world [1,2]. Many strategies have been reported to improve cure efficiency, such as drug-eluting stents (DES) [6], stent-based gene therapy [7], endothelial progenitor cell-capture stents (EPC) [8], bioresorbable scaffolds (BRS) [9] and so on. These stents played a very important role and showed promising prospects in the treatment of restenosis, today DES is still the major

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.